IBB:NSD-iShares Biotechnology ETF (USD)

ETF | Health |

Last Closing

USD 142.18

Change

-1.72 (-1.20)%

Market Cap

USD 7.46B

Volume

0.97M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

The fund generally will invest at least 80% of its assets in the component securities of its underlying index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents. It is non-diversified.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-07 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
PPH VanEck Pharmaceutical ETF

-0.17 (-0.18%)

USD 0.71B
BBH VanEck Biotech ETF

-2.04 (-1.16%)

USD 0.45B
PSCH Invesco S&P SmallCap Health Ca..

-0.79 (-1.75%)

USD 0.19B
PTH Invesco DWA Healthcare Momentu..

-0.92 (-2.01%)

USD 0.15B
GNOM Global X Genomics & Biotechnol..

-0.14 (-1.27%)

USD 0.08B
FTXH First Trust Nasdaq Pharmaceuti..

-0.23 (-0.81%)

USD 0.02B
CNCR Loncar Cancer Immunotherapy ET..

-0.43 (-2.88%)

USD 0.01B

ETFs Containing IBB

IBB3:LSE 300.12 % 0.00 %

N/A

N/A
HAC.A:CA 0.00 % 3.14 %

N/A

N/A
HAC:CA Global X Seasonal Rotatio.. 0.00 % 1.27 %

-0.02 (0%)

CAD 0.22B
IBBS:LSE -299.94 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -65.11% 25% F 9% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return -65.11% 25% F 9% A-
Trailing 12 Months  
Capital Gain -61.17% 25% F 11% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -61.17% 25% F 11% F
Trailing 5 Years  
Capital Gain -51.52% 25% F 22% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -51.52% 25% F 22% F
Average Annual (5 Year Horizon)  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) N/A N/A N/A N/A N/A
Risk Adjusted Return N/A N/A N/A N/A N/A
Market Capitalization 7.46B 100% F 91% A-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:

There is nothing we particularly dislike